top of page

A Bioelectronic Medicine Company

advancing the treatment of autoimmune disease.


About Us

Boomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt the treatment of autoimmune diseases. The company is developing a bioelectric neuromodulation technology, which has been granted Breakthrough Device Designation by the FDA for the treatment of Crohn's disease and ulcerative colitis. The technology is being evaluated in a multi-center, single-arm clinical trial at leading IBD centers in the US.


Headquartered in the heart of Silicon Valley on the campus of El Camino Hospital, Boomerang is a Company-In-Residence at the prestigious Fogarty Innovation incubator–the only healthcare-focused incubator/accelerator of its kind in the US–giving us access to the brightest minds and expertise in the medical technology industry.

Our Focus

The rate of autoimmune diseases in the U.S. population has been increasing for several decades. Recent research estimates that 51 million people in the U.S. (16% of the U.S. population) may be affected by a full-clinical or pre-clinical autoimmune disease. While the etiologies of most autoimmune diseases remain unknown, it has been well described that once triggered, the body is unable to balance its immune response. The body begins to mistake its own healthy tissue as foreign, and mounts an inappropriate attack against itself. In a normal immune state, the nervous system and immune system act in harmony to defend the body from pathogens and then return the body to stability, otherwise referred to as homeostasis. When there is an inability to appropriately regulate an immune response, homeostasis is lost and an autoimmune reaction triggered. Over time, this hyperimmune state can lead to chronic inflammation and subsequent tissue damage. The result of this process is manifested in a variety of disease states, such as inflammatory bowel disease (Crohn's disease and ulcerative colitis) and rheumatoid arthritis. Bioelectronic medicine focuses on electric signaling within the nervous system to assist the body in restoring homeostasis, with the goal of obviating chronic inflammatory pathways.


Does Inflammatory Bowel Disease disrupt your daily life?

Researchers in the BOOM-IBD Clinical Trial are exploring whether nerve stimulation, a therapy already approved by the FDA to treat other conditions, can be effective for treating Inflammatory Bowel Disease.

Meet the Team


Board of Directors + Advisors

Boomerang Medical is proud to be a portfolio company of Arboretum Ventures and Hatteras Venture Partners, as well as a Company In Residence at Fogarty Innovation


Heather Simonsen

Boomerang Medical

President & CEO


Andrew Cleeland

Fogarty Innovation

Chief Executive Officer

tom shehab_edited.png

Tom Shehab, MD

Arboretum Ventures

Managing Partner

gayle headshot_edited_edited.png

Gayle Kuokka

Fogarty Innovation

Chief Financial Officer

jeff terrell headshot_edited_edited.png

Jeff Terrell

Hatteras Venture Partners

General Partner

Screen Shot 2022-10-10 at 11_edited_edit

John Morriss

Fogarty Innovation

Director of Innovation Acceleration


Bioelectronic Medicine Company Boomerang Medical Raises $15M Series A Financing

Boomerang Medical Receives FDA IDE Approval to Begin Study of Bioelectronic Therapy

Boomerang Medical Appoints Pharoah Garma as Chief Operating Officer

Boomerang Medical Names Medtech Veteran Heather Simonsen as CEO and Closes $3M Seed Financing

2495 Hospital Drive, Suite 300

Mountain View, CA 94040


bottom of page